我們已在上線！進一步了解

Ligand Pharmaceuticals

LGND

市值 US$58.9億

295.54 USD

-2.96

0.99%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

295.54

0.00

0%

1天

-0.99%

5天

-2.3%

1個月

7.39%

3個月

-0.31%

6個月

32.39%

今年迄今

55.46%

1年

63.49%

5年

268.46%

10年

407.19%

關於： Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

員工： 47

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 23.1%

中性 76.9%

負面 0%

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments an.

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital.

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.

Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million

Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is highlighted as a reliable midcap pharma with a high-growth business model.

Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m.

Ligand to Participate in September Investor Conferences

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

查看新聞排名

價格圖表採用Lightweight Charts™實作